The study investigates the association between the recombinant shingles vaccine and the risk of dementia. Using a natural experiment created by the rapid transition from live to recombinant vaccines in the United States, the researchers compared the incidence of dementia in those who received the recombinant vaccine with those who received the live vaccine. The results show that the recombinant shingles vaccine is associated with a significantly lower risk of dementia, with a 17% increase in diagnosis-free time, translating to 164 additional days without a dementia diagnosis. This effect was more pronounced in women than in men. The study also found that the recombinant vaccine was associated with a lower risk of dementia compared to influenza and tetanus-diphtheria-pertussis vaccines. The findings suggest that the recombinant shingles vaccine may offer additional protection against dementia and warrant further investigation through randomized controlled trials.The study investigates the association between the recombinant shingles vaccine and the risk of dementia. Using a natural experiment created by the rapid transition from live to recombinant vaccines in the United States, the researchers compared the incidence of dementia in those who received the recombinant vaccine with those who received the live vaccine. The results show that the recombinant shingles vaccine is associated with a significantly lower risk of dementia, with a 17% increase in diagnosis-free time, translating to 164 additional days without a dementia diagnosis. This effect was more pronounced in women than in men. The study also found that the recombinant vaccine was associated with a lower risk of dementia compared to influenza and tetanus-diphtheria-pertussis vaccines. The findings suggest that the recombinant shingles vaccine may offer additional protection against dementia and warrant further investigation through randomized controlled trials.